Thrombopoietin: An update on therapeutic potential

BioDrugs

Volumn 11, Issue 4, 1999, Pages 261-276

  Underhill, Craig R ^a   Basser, Russell L ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPOIETIN;

CANCER; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 0032925287     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911040-00005     Document Type: Review

References (110)

1. 1. Keleman E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol (Basel) 1958; 20: 350-5
2. 2. McDonald TP. Thrombopoietin: its biology, purification and characterisation. Exp Hematol 1988; 16: 201-5
3. 3. Wendling F, Varlet P, Charon M, et al. A retrovirus complex inducing an acute myeloproliferative leukemia disorder in mice. Virology 1986; 149: 242
4. 4. Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic precursors. Cell 1990; 63: 1137
5. 5. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992; 89: 5640
6. 6. Methia N, Louache F, Vainchencker W, et al. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395
7. 7. Je Sauvage FJ, Mass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombocytopoeisis by the c-Mpl ligand. Nature 1994; 369: 533-8
8. 8. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-8
9. 9. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 1994; 77: 1117-24
10. 10. SohmaY, Akahori H, Seki N, et al. Molecular cloning and chromosomal localisation of human thrombopoietin gene. FEBS Lett 1994; 353: 57-61
11. 11. Kato T, Iwamatsu A, Shimada Y. Purification and characterization of thrombopoietin derived from thrombocytopenic rat plasma [abstract]. Blood 1994; 84 Suppl. 1: 329a
12. 12. Kuter DJ, Beeler DL, Rosenburg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 1104
13. 13. Lok S, Foster D. The structure, biology and therapeutic applications of recombinant thrombopoietin. Stem Cells 1994; 12: 586-98
14. 14. Gurney AL, Kuang WJ, Xie MH, et al. Genomic structure, chromosomal characterization and conserved alternative splice forms of thrombopoietin. Blood 1995; 85: 981-8
15. 15. Solberg LA Jr, Wilson D, De Sauvage F, et al. Effects of recombinant human thrombopoietin (rhTPO) on human haematopoietic cells [abstract]. Blood 1994; 84: 330a
16. 16. Foster D, Lok S. Biological roles for the second domain of thrombopoietin. Stem Cells 1996; 14 Suppl. 1: 102-7
17. 17. Gurney AL, Kuang W-K, Xie M-H, et al. Genomic structure, chromosomal localisation and conserved alternative splice forms of thrombopoietin. Blood 1995; 85: 981-8
18. 18. Hokom MM, Lacey D, Kinstler OB, et al. Peglylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86 (12): 4486-92
19. 19. Vadhan-Raj S, Murray LJ, Buesos-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126 (9): 673-81
20. 20. Kuter DJ. The physiology of platelet production. Stem Cells 1996; 14 Suppl. 1: 88-101
21. 21. Brecher G, Scneiderman M, Cronkite EP. The reproducibility and constancy of the platelet count. Am J Clin Pathol 1953; 23: 15-26
22. 22. Giles C. The platelet count and mean platelet volume. Br J Haematol 1981; 48: 31-7
23. 23. von Behrens WE. Mediterranean macrothrombocytopenia. Blood 1975; 46: 199-208
24. 24. Bessman JD, Williams LJ, Gilmer PR. The inverse relation of platelet size and count in normal subjects and an artefact of other particles. Am J Clin Pathol 1981; 76: 289-93
25. 25. Thompson CB. From precursor to product: how do megakaryocytes produce platelets? Prog Clin Biol Res 1986; 215: 361-71
26. 26. Harker LA. Kinetics of thrombocytopoiesis. J Clin Invest 1968; 47: 458-65
27. 27. Jackson JW, Brown LK, Somerville BC, et al. Two-color flow cytometric measurement of DNA distribution of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. Blood 1984; 63: 768-78
28. 28. Kuter DJ, Rosenburg RD. Regulation of megakaryocyte ploidy in vivo in the rat. Blood 1990; 75: 74-81
29. 29. Foster D, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression and chromosomal localization. Proc Natl Acad Sci 1994; 91: 13023-7
30. 30. Debili N, Wendling F, Cosman D, et al. The mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85: 391-401
31. 31. Broudy VC, Lin NL, Sabath DF, et al. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89: 1896-904
32. 32. Vigon I, Dreyfus F, Melie J. Expression of the c-mpl protooncogene in human hematologic malignancies. Blood 1993; 82: 877-83
33. 33. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995; 55: 3509-12
34. 34. Kaushansky K, Lok K, Holly R, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369 (6481): 568-71
35. 35. Zeigler FC, De Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84: 4045-52
36. 36. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85: 1719-26
37. 37. Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor. J Clin Invest 1995; 95: 2973-8
38. 38. Banu N, Wang JF, Deng B, et al. Modulation of megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand. Blood 1995; 86 (4): 1331
39. 39. Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vivo from pro-platelets displaying human megakaryocytes are functional. Blood 1995; 85: 402-13
40. 40. Angchaisuksiri P, Carlson PL, Dessypris EN. Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Br J Haematol 1996; 93: 13-7
41. 41. Debili N, Wendling F, Katz A, et al. The mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86 (7): 2516-25
42. 42. Eaton DL, De Sauvage F. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 1997; 25: 1-7
43. 43. Ulich TR, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86 (3): 971-6
44. 44. Kuter DJ, Rosenberg RD. The reciprocol relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulphan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30
45. 45. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting factor, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994; 84: 1464-72
46. 46. Wendling F, Maraskovsky E, Debili N. C-mpl ligand is a humoral regulator of megakaryopoiesis. Nature 1994; 369: 571-4
47. 47. De Sauvage F, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183: 651-6
48. 48. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl mediated binding to platelets. Blood 1996; 87: 2154-61
49. 49. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567-73
50. 50. Gurney AL, Carver-Moore K, De Sauvage F, et al. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445-7
51. 51. Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hemopoietic lineages and defective megakaryopoiesis in mice lacking the thrombopoietin receptor c-mpl. Blood 1996; 87: 2162-70
52. 52. Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin and c-mpl deficient mice. Blood 1996; 88: 803-8
53. 53. Kaushansky K, Lin NL, Grossman A, et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996; 24: 254-69
54. 54. Arnold JT, Daw NC, Stenberg PE, et al. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size and ploidy. Blood 1997; 89 (3): 823-33
55. 55. Kaushansky K, Broudy VC, Grossman A, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96: 1683-7
56. 56. Papayannopoulou T, Brice M, Farrer D, et al. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol 1996 Apr: 24 (5): 660-9
57. 57. Sprugel KH, Ren HP, Osherhoff M. Recombinant human thrombopoietin stimulates platelet responses in cynomologous monkeys. Blood 1995; 86 Suppl. 1: 20a
58. 58. Farese M, Hunt P, Boone T, et al. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86 (1): 54-9
59. 59. Harker LA, Hunt P, Marzec U, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87 (5): 1833-44
60. 60. Harker LA, Marzec U, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88 (2): 511-21
61. 61. Ault K, Knowles C. Recombinant thrombopoietin induces a dose response increase in reticulated platelets which precedes the increase in platelet count, and does not affect platelet lifespan in mice [abstract]. Blood 1995; 86 Suppl. 1: 367a
62. 62. Harker LA, Marzec UM, Kelly AB, et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997; 89 (1): 155-65
63. 63. Farese AM, Hunt P, Grab LB, et al. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation induced marrow aplasia. J Clin Invest 1996; 97 (9): 2145-51
64. 64. Akahori H, Shibuya K, Obuchi M, et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996; 94: 722-8
65. 65. Grossman A, Lenox J, Ren HP, et al. Thrombopoietin accelerates platelet, red blood cell and neutrophil recovery in myelosuppressed mice. Exp Hematol 1996; 24: 1238-46
66. 66. Grossman A, Lenox J, Deisher TA, et al. Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice. Blood 1996; 88 (9): 3363-70
67. 67. Kabaya K, Shibuya K, Torii Y, et al. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice. Bone Marrow Transplant 1996; 18: 1035-41
68. 68. Fibbe WE, Heemskerk DPM, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86 (9): 3308-13
69. 69. Molineux G, Hartley C, McElroy P, et al. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996; 88 (1): 336-76
70. 70. Koyabashi M, Laver JH, Kato T, et al. Recombinant human thrombopoietin (mpl ligand) enhances proliferation of erythroid progenitors. Blood 1995; 86: 2494-9
71. 71. Chen J, Herceg-Harjacek L, Groopman J, et al. Regulation of platelet activation in vitro by c-Mpl ligand, thrombopoietin. Blood 1995; 86 (11): 4054-62
72. 72. Kojima H, Hamazaki Y, Nagata Y, et al. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74 (6): 1541-5
73. 73. Toombs CF, Young CH, Glaspy JA, et al. Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation. Thromb Res 1995; 80 (1): 23-33
74. 74. Montrucchio G, Brizzi MF, Calosso G, et al. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87 (7): 2762-8
75. 75. Rodriguez-Linares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phophorylation. Biochem J 1996; 316: 93-8
76. 76. Kobuta Y, Arai T, Tanka T, et al. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 1996; 14: 439-44
77. 77. Oda A, MiYakawa Y, Druker B, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87 (11): 4664-70
78. 78. Broudy VC, Lin NL, Kox N, et al. Thrombopoietin stimulates colony-forming unit megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. Blood 1996; 88: 2026-32
79. 79. Cramer, Norol F, Guichard J, et al. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood 1997; 89: 2336-46
80. 80. Horie K, Miyazaki H, Hagiwara T, et al. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Exp Hematol 1997; 25: 169-76
81. 81. Yan XQ, Lacey D, Fletcher F et al. Chronic exposure to retroviral encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86 (11): 4025-33
82. 82. Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mRNA in the liver by in-situ hybridization. Exp Hematol 1997; 25: 565-72
83. 83. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow,and spleen using in situ hybridization. Blood 1997; 89: 101-7
84. 84. Zhou W, Toombs CF, Zou T, et al. Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment. Blood 1997 Mar; 89: 1551-9
85. 85. Basser R, Rasko JEJ, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348; 1279
86. 86. D'Hondt V, Humblet Y, Guillame T, et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo controlled, randomized phase Ib study. Blood 1995; 85: 2347-5
87. 87. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756-61
88. 88. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615-24
89. 89. Biesma B, Willemse PH, Mulder NH, et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992; 80: 1141-8
90. 90. Veldhuis GJ, Willemse PH, Sleijfer DT, et al. Toxicity and efficacy of escalating doses of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small cell lung cancer. J Clin Oncol 1995; 13: 2585-93
91. 91. Vadhan-Raj S. Papadopoulous NE, Burgess MA, et al. Effects of P1XY321, a granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 1994; 13: 2585-93
92. 92. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-14
93. 93. Fanucchi MH, Glaspy J, Garst J, et al. Effects of polyethyleneglycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336 (6): 404-9
94. 94. Basser RL, Clarke K, Rasko JEJ, et al. Randomised, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118-28
95. 95. Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989; 7: 1554-62
96. 96. Rasko JEJ, Basser RL, Boyd J, et al. Multilineage mobilization of peripheral blood progenitor cells following administration of PEG-rHUMGDF. Br J Haematol 1997; 97: 871-80
97. 97. Sheridan WP, Begley CG, Juttner C, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4
98. 98. De Luca E, Sheridan WP, Watson D, et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992; 66: 893-9
99. 99. Vadhan-Raj S, Kudelka AP, Garrison L, et al. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994; 12: 707-14
100. 100. Basser RL, Begley CG, Mansfield R, et al. Mobilization of PBPC by priming with stem cell factor (SCF) before filgrastim compared to concurrent administration [abstract]. Blood 1995; 86 Suppl. 1: 687a
101. 101. O'Malley CJ, Rasko JEJ, Basser R, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88: 3288-98
102. 102. Postmus P, Gietma JA, Damsma O, et al. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study. J Clin Oncol 1992; 10: 1131-40
103. 103. Bunn PA Jr, Ridgeway EC, De Vita VT Jr, et al. Paraneoplastic syndromes. In: De Vito Jr VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippincott, 1993; 2026
104. 104. Wolff S, Lynch J, Herzig R, et al. Safety and activity of recombinant human thrombopoietin (rhTPO) in patients receiving autologous bone marrow transplant (ABMT): preliminary results of a phase I/II trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 109a
105. 105. Archimbaud E, Ottmann O, Liu Yin JA, et al. A randomised, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with denovo acute myeloid leukaemia: early results [abstract]. Blood 1997; 88 (10 Suppl. 1): 447a
106. 106. Rose EH, Abels RI, Nelson RA, et al. The use of rHuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995; 89: 931
107. 107. Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545
108. 108. Negrin RS, Hauber DH, Nagler A. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1992; 110: 976
109. 109. Chang M, Suen Y, Meng G, et al. Differential mechanisms in the regukation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood 1996; 88: 3354-62
110. 110. Ratner L. Human immunodeficiency virus-associated autoimmune thrombocytopenic purpura: a review. Am J Med 1989; 86: 194